Core Viewpoint - Hunan Warner Pharmaceutical Co., Ltd. has participated in the national organized procurement of drugs and has announced that several of its products are proposed to be selected for the continuation of procurement after the expiration of the previous agreement [1][3]. Group 1: Proposed Selected Products - The company has a total of 12 products proposed for selection in this procurement process [3]. - The procurement cycle for the selected products will last until December 31, 2028, starting from the actual execution date of the selection results [2]. Group 2: Financial Impact - The projected sales revenue from the selected products is estimated to be 176.18 million yuan for 2024, accounting for 12.47% of the company's total revenue for that year [3]. - For the period from January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [3]. - The selected products are expected to enhance the company's market share and brand influence as medical institutions will prioritize these products during the procurement cycle [3].